The detection of BRAF mutation in MM using new sequencing techniques is mandatory in order to identify the eligibility of MM patients for the application of targeted therapies with BRAF inhibitors and to monitor their therapy responses or the development of therapy resistance. This evidence concerns the gene BRAF and Miyoshi myopathy.